VSTM Report3 PDF

Verastem Oncology
CORTELLIS COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.
Publication Date: 02-Sep-2018
CLARIVATE ANALYTICS
1500 Spring Garden
Philadelphia, PA 19130
United States
Tel: +1 888 537 6110
clarivate.com
Return to Table of Contents
© 2018 Clarivate Analytics

ABOUT COMPANY AND PIPELINE OVERVIEW REPORT
Clarivate Analytics provides the knowledge, tools, and expertise to help support drug discovery and
development activities, IP portfolio optimization, identification of licensing and partnering opportunities,
delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing
pharmaceutical and chemical markets, supporting informed, early decisions.
This report was created by Clarivate, using information from Cortellis for Competitive Intelligence; a
comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely
respected drug pipeline information.From drug discovery and development activities to patent reports, the
latest deals, and partnering opportunities, Cortellis can provide the confidence to make the most informed
business decisions, faster. Cortellis for Competitive Intelligence provides accurateand validated information
on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical
trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive
research platform.
Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical
and biotechnology companies worldwide. Further report offerings planned to follow include: Company
Detailed Pipeline and Company Competitive Landscape reports. All Cortellis for Competitive Intelligence
content is subject to the most comprehensive editorial review process available, conducted by scientists,
pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline
information expertly uncovered and integrated from a significant number of global meetings each year, you’ll
always be on top of the latest developments.
Chosen by leading life sciences companies, their executives and investors, Cortellis for Competitive
Intelligence accelerates your deal-making and gives you timely insights on the development landscape.
Discover undiscovered opportunities in drug development and licensing faster with Cortellis for
Competitive Intelligence
DISCLAIMER
The information contained in this report is based on sources believed to be correct but Clarivate Analytics
does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those
held by the author of any individual report or article at the time of initial publication and do not necessarily
reflect the views of Clarivate.
Information in this report on companies is intended for reference use only, and does not constitute a
recommendation to buy or sell any particular security or other investment and does not constitute an offer to
buy from or sell to any particular investor. Any company or securities mentioned in this report may not be
suitable for any particular investor, depending on that investor's financial position and needs.
© 2018 Clarivate Analytics 2

GLOSSARY
Number of Drugs in Active Development
Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the
development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III,
Pre-registration, Registered, Launched, or Suspended.
Number of Inactive Drugs
Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e.
where the development status for the drug(s) is one of the following: No Development Reported,
Discontinued, or Withdrawn.
Number of Patents as Owner
Number of patents associated with the company where the company is listed as owner; i.e. the relationship
type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee),
Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family
member, Inferred assignee.
Number of Patents as Third Party
Number of patents associated with the company where the company is listed as third party; i.e. the
relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for
development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-
Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying
technology.
Patents summary table
This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US
and WO patents since 1990 only.
Number of Deals
A count of deals where the company or one of its subsidiaries is the primary company.
Key Indications
Displays top ten key indications for the company and its subsidiaries based on frequency (indications
occurring with high and identical frequency are always included, and this may result in more than ten Key
Indications being listed). Includes both indications associated with patents where the company is patent
owner and indications associated with drugs in active development. A drug is classified as 'active' if it
features on a row (or rows) in the current development status table where the status is one of the following:
Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.
Key Target-based Actions
Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions
Target-based Actions being listed). Includes both target-based actions associated with patents where the
company patent owner and target-based actions associated with drugs in active development. A drug is
classified as 'active' if it features on a row (or rows) in the current development status table where the status
is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered,
Launched, or Suspended. A target-based action is one that is associated with a target.
Key Technologies
Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies
Technologies being listed). Includes both key technologies associated with patents where the company
relationship is patent owner and key technologies associated with drugs in active development. A drug is
classified as 'active' if it features on a row (or rows) in the current development status table where the status
is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered,
Launched, or Suspended.

PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock
Performance chart (including the consensus recommendation), and Major Shareholders. Financial
Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income
over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and
Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all
sections (except share information and major stock holders) are correct as of the publication date of the
report (and not the download date). For share information and major stock holders the data is correct for the
date shown with these sections

TABLE OF CONTENTS
Company Overview........................................................................................................................... 7
Company Profile................................................................................................................................ 7
Company Financials.......................................................................................................................... 8
Product Portfolio Summary............................................................................................................... 13
Product Portfolio Financials.............................................................................................................. 18
Product Portfolio Drugs..................................................................................................................... 19

Verastem Oncology
COMPANY OVERVIEW
Company Name Verastem Oncology
Parent Company Name Verastem Oncology
Website http://www.verastem.com/
Country US
Number of Drugs in Active
Development 5
Number of Inactive Drugs 3
Number of Patents as Owner 11

Number of Patents as Third
Party 1
Number of Deals 17
Cancer,Non-small-cell lung cancer,Mesothelioma,Ovary tumor,Pancreas
Key Indications tumor,Follicle center lymphoma,Chronic lymphocytic leukemia,Non-Hodgkin
lymphoma,Peripheral T-cell lymphoma,Solid tumor,T-cell lymphoma
Wnt ligand inhibitor,Focal adhesion kinase inhibitor,Beta-catenin
inhibitor,mTOR inhibitor,Phosphoinositide 3-kinase inhibitor,ATP dependent
Key Target-based Actions
RNA helicase DDX43 inhibitor,MEK protein kinase inhibitor,Phosphoinositide-3
kinase alpha inhibitor,Wnt ligand modulator,mTOR complex 1 inhibitor
Small molecule therapeutic,Natural product,Hybridization technology,Drug
combination,Immunodetection,PCR based technology,Antibody,DNA
Key Technologies hybridization,Formulation preservation,Isolation technology,Monoclonal
antibody,Oral absorption enhancer,Oral formulation,Oral quick release
formulation,RNA sequencing technology,Tablet formulation
COMPANY PROFILE
SUMMARY
Verastem Oncology (previously known as Verastem Inc) is a biopharmaceutical company focused on discovering and
developing drugs targeting cancer stem cells.
In October 2015, Verastem announced a reduction of its workforce by approximately 50% to 20 full time employees.
In May 2018, the company changed its name to "Verastem Oncology" to reinforce its commitment to developing and
commercializing treatment options for patients battling cancer.
FINANCIAL
In June 2018, Verastem was admittted to the broad-market Russell 3000 Index, at the conclusion of the Russell US
Indexes annual reconstitution.
In June 2018, the company registered sale to funds managed by Consonance Capital of 7,166,666 shares of the
company's common stock at a price of $6.00 per share. The gross proceeds to from the offering were expected to be
approximately $43.0 million. The offering was subject to customary closing conditions and was expected to close on
June 18, 2018.
In May 2018, the company commenced a registered underwritten public offering of $35 million of shares of common
stock and had granted the underwriter a 30-day option to purchase up to an additional $5.25 million shares of common
stock. Later that month, the company priced the offering of 7,777,778 shares of its common stock at a public price of
$4.50 per share. The Underwriters were granted a 30-day option to purchase up to an additional 1,166,666 shares of its
common stock. The gross proceeds from the offering were expected to be $35 million. The offering was expected to
close on or about May 18, 2018; again later that month, the company announced closing of underwriters option to
purchase additional shares and the raised aggregate gross proceeds from the offering, including the full exercise of the
underwriters option were expected to be $40.2 million. In May 2018, the net proceeds from the offering were $38.3
million.

In December 2017, Verastem planned a $25 million underwritten public offering of its common stock; later that month,
the underwritten public offering was priced, and the offering was expected to close on or about December 19, 2017.
In March 2017, the company secured a $25 million Loan and Security Agreement with Hercules Capital and received the
first $2.5 million of financing. At that time, additional tranches of up to $22.5 million in aggregate was to be given on
fulfillment of certain conditions. As of March 31 2017, the company had 36,992,418 outstanding common shares. In
January 2018, Verastem increased the borrowing limit under the loan facility from $25 million to $50 million.
In January 2015, the company expected to offer and sell $40 million of its common stock in an underwritten public
offering. At that time, there was no assurance on the completion of the offering. Later that month, the company planned
to raise net proceeds of $44.1 million from the offering of 7.25 million shares, priced at $6.50 per share. The underwriters
were granted a 30-day option to purchase up to 1,087,500 additional shares of common stock. At that time, the offering
was expected to close on or about January 28, 2015. Later in January 2015, the offering of 8,337,500 shares was
closed, and the company raised gross proceeds of $54.2 million.
In July 2013, Verastem announced a public offering of 3.7 million shares of common stock, at a price of $15.00 per
share; net proceeds of $51.9 million were expected. Underwriters were to be granted a 30-day option to purchase an
addition 555,000 shares. Later that month, Verastem closed the $63.8 million underwritten public offering of 4,255,000
shares of common stock, including 555,000 shares of common stock which were issued pursuant to the exercise of the
underwriters' option to purchase additional shares, priced at $15.00 per share. The net proceeds were approximately
$59.8 million.
By December 2012, Verastem had raised $63.5 million gross proceeds in an initial public offering.
In November 2012, Verastem planned a pre-arranged personal stock purchasing plan to acquire its common stock
shares. At that time, the transaction was expected to commence on December 21, 2012.
In March 2012, the company was added to the Russell 2000 index.
In November 2011, Verastem filed a registration statement for the proposed IPO of its common stock. In January 2012,
the Securities and Exchange Commission declared the registration effective, and the company priced the IPO of 5.5
million shares at $10.00 per share, with underwriters granted a 30-day option to purchase an additional 825,000 shares
of common stock to cover overallotments. The shares were to begin trading on the NASDAQ global market on January
27, 2012 under the symbol "VSTM"; in February 2012, underwriters fully exercised their over-allotment option for the
purchase of additional common stocks shares. Net proceeds from the IPO were approximately $56.7 million. In
December 2013, NASDAQ reported that, Verastem would be added to the NASDAQ Biotechnology Index, under the
trading symbol 'VSTM', as a result of the annual re-ranking, which would become effective prior to market open on
December 23, 2013; later that month, Verastem was added to NASDAQ Biotechnology Index and would be active from
December 23, 2013.
In July 2011, Verastem raised $32 million from a series B financing.
In November 2010, Verastem raised $16 million from a series A financing.
COMPANY FINANCIALS
SHARE INFORMATION
Close Price (USD)
Change (USD)
Previous Close Price (USD)
Volume 0
52-Week High (USD)
52-Week Low (USD)
Date
Exchange

Current Number of Shares
73,580,000
Outstanding
Current Market
690,180,400
Capitalization
EPS (Date Reported) -1.76467
STOCK PERFORMANCE
MAJOR SHAREHOLDERS
Shareholder Type Country Shares % of Change in % changes Date

held shares holding in shares
held held
Fidelity Select Mutual United

3,101,997 4.22 0 0 31-Jul-2018
Biotechnology Portfolio Fund States
Vanguard Total Stock Mutual United

1,540,076 2.09 0 0 31-Jul-2018
Market Index Fund Fund States
iShares Russell 2000 Mutual United

1,102,498 1.5 -22,261 -0.02 31-Jul-2018
ETF Fund States
Vanguard Extended Mutual United

904,913 1.23 211,800 0.31 31-Jul-2018
Venture Netherla
Life Sciences Partners 873,201 1.19 0 0 31-Jul-2018
Capital nds
LSP Life Sciences Fund Mutual Netherla

873,201 1.19 0 0 31-Jul-2018
N.V. Fund nds

Fidelity Advisor Mutual United
636,057 0.86 -320,043 -0.33 31-Jul-2018
Biotechnology Fund Fund States
iShares Russell 2000 Mutual United

499,853 0.68 -11,063 -0.02 31-Jul-2018
Growth ETF Fund States
Invesco DWA
Mutual United
Healthcare Momentum 422,222 0.57 422,222 1 31-Jul-2018
Fund States
ETF
Fidelity Extended Mutual United

310,015 0.42 59,116 0.24 31-Jul-2018
PowerShares DWA
Mutual United
SmallCap Momentum 187,264 0.25 187,264 1 31-Jul-2018
Fund States
Portfolio
Fidelity Total Market Mutual United

140,678 0.19 47,287 0.51 31-Jul-2018
Index Fund Fund States
Mutual United
iShares Micro-Cap ETF 139,403 0.19 4,080 0.03 31-Jul-2018
Fund States
Columbia Active
Portfolios Multi Mutual United
110,661 0.15 -55,868 -0.34 31-Jul-2018
Manager Small Cap Fund States
Equity Fu
SEI Institutional
Mutual United
Managed - Small Cap 106,000 0.14 0 0 31-Jul-2018
Fund States
Fund
Victory RS Science and Mutual United

101,830 0.14 0 0 31-Jul-2018
Technology Fund Fund States
Virtus LifeSci Biotech Mutual United

95,308 0.13 -47,880 -0.33 31-Jul-2018
Clinical Trials ETF Fund States
Vanguard Institutional
Mutual United
Total Stock Market 94,508 0.13 0 0 31-Jul-2018
Fund States
Index Fund
Investme
Wellington nt
United
Management Advisor/ 81,600 0.11 81,600 1 31-Jul-2018
States
Company, LLP Hedge
Fund
SEI Inst Inv Small Cap Mutual United

81,030 0.11 81,030 1 31-Jul-2018
II Fund Fund States

FINANCIAL PERFORMANCE
2013 2016 2015 2014 2017
Sales (USD M) 0 0 0 0 0
Operating Income (USD M) -41.402 -37.002 -58.199 -53.607 -67.804
Net Income (USD M) -41.202 -36.44 -57.865 -53.365 -67.802

Quarterly earnings update
Period Sales (USD M) Operating Income (USD M) Net Income (USD M)
2018 Q2 10 -18.194 -18.367
2018 Q1 0 -20.761 -21.05
2017 Q4 0 -18.052 -18.235
2017 Q3 0 -23.137 -23.126
2017 Q2 0 -13.467 -13.436
2017 Q1 0 -13.148 -13.005
2016 Q4 0 -11.8 -11.655
2016 Q3 0 -8.059 -7.922
2016 Q2 0 -8.709 -8.569
2016 Q1 0 -8.434 -8.294
BALANCE SHEET
Assets (USD M)
2013 2014 2015 2016 2017
Cash & Short Term

101.398 92.675 110.258 80.897 86.672
Investments
Inventories - Total 0 0 0 0 0
Current Assets - Total 101.955 95.316 110.843 81.295 87.787
Property, Plant And

0.631 2.825 2.048 1.417 0.861
Equipment - Net
Other Assets - Total 0.331 0.305 0 0.755 0.981
Total Assets 125.261 98.649 113.094 83.629 89.791

Liabilities (USD M)
2013 2014 2015 2016 2017
Accounts Payable 2.76 3.216 3.942 4.095 9.186
Short Term Debt &

Current Portion Of Long 0 0 0 0 0
Term Debt
Current Liabilities - Total 7.804 9.204 10.109 10.991 17.128
Long Term Debt 0 0 0 0 14.828
Other Liabilities 0.011 0.679 0.516 0.341 0.151
Total Liabilities 7.815 9.883 10.625 11.332 32.107
Stockholders Equity (USD M)
2013 2014 2015 2016 2017
Minority Interest 0 0 0 0 0
Preferred Stock 0 0 0 0 0
Common Stock 0.003 0.003 0.004 0.004 0.005
Treasury Stock 0 0 0 0 0
Total Liabilities &

125.261 98.649 113.094 83.629 89.791
Shareholders' Equity
FORECASTS
EPS Forecast
Year ending Current Forecast 1 month ago 3 months ago
31-Dec-2018 -1.65 -1.45 -1.52
31-Dec-2019 -1.15 -0.98 -1.28
31-Dec-2020 -0.52 -0.34 -0.62
Other Forecasts
Year ending DPS CPS Pretax Sales
31-Dec-2018 0 -1.57 -106.43 5.69
31-Dec-2019 0 -0.63 -80.15 42.53
31-Dec-2020 0.48 -29.23 103.33

PRODUCT PORTFOLIO SUMMARY
DRUGS
Drugs by Indication
Active Drugs by Indication Chart

Drugs by Indication Table
Indication Active Inactive Total
Neoplasm 5 3 8
Respiratory disease 3 0 3
Rare disease 3 0 3
Hematological disease 1 0 1
Immune disorder 1 0 1
Gastrointestinal disease 1 0 1
Gynecology and obstetrics 1 0 1
Endocrine disease 1 0 1
Genitourinary disease 1 0 1
Drugs by Highest Status
Active Drugs by Highest Status Chart

Drugs by Highest Status Table
Development Status Number of Drugs
Pre-registration 1
Phase 2 Clinical 1
Phase 1 Clinical 2
Discovery 1
No Development Reported 3
DEALS
Deal Type Principal Partner Total

Active Inactive Active Inactive
Drug - Development Services 0 0 1 0 1
Drug - Screening/Evaluation 1 0 1 0 2
Drug - Development/Commercialization License 2 0 6 0 8
Technology - Other Proprietary 1 0 0 0 1
Drug - Discovery/Design 0 0 1 0 1
Patent - Non-Exclusive Rights 0 0 1 0 1
Patent - Exclusive Rights 0 0 1 0 1
Drug - Asset Divestment 0 0 1 0 1
Drug - Funding 1 0 0 0 1
CLINICAL TRIALS
Trials by Condition Studied
Condition Studied Ongoing All
Neoplasm 12 32
Hematological disease 8 17
Immune disorder 4 14
Rare disease 4 10
Respiratory disease 2 7
Endocrine disease 2 5

Gastrointestinal disease 3 5
Genitourinary disease 2 5
Gynecology and obstetrics 2 4
Inflammatory disease 0 2
Andrology 0 1
Musculoskeletal disease 0 1
Trials by Phase
Phase Ongoing All
Phase 3 2 4
Phase 2 5 12
Phase 1 5 24
Phase Definitions
Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)
Phase 2 Clinical
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is
under 300 or not specified)
Phase 1 Clinical
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0
PATENTS *
Indication As Owner As Third Party Total
Immune disorder 7 0 7
Musculoskeletal disease 4 0 4
Neoplasm 15 1 16
Ocular disease 2 0 2
Inflammatory disease 6 0 6
Metabolic disorder 3 0 3
Neurological disease 5 0 5
Nutritional disorder 1 0 1
Respiratory disease 6 0 6
Infectious disease 3 0 3

Cardiovascular disease 4 0 4
Endocrine disease 10 1 11
Gastrointestinal disease 7 0 7
Genitourinary disease 5 0 5
Hematological disease 9 0 9
Andrology 3 0 3
Dermatological disease 7 0 7
Otorhinolaryngological disease 1 0 1
Gynecology and obstetrics 7 1 8
Rare disease 7 0 7
* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since
1990 only.

PRODUCT PORTFOLIO FINANCIALS
DRUG SALES AND FORECASTS

PRODUCT PORTFOLIO DRUGS
PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies
duvelisib
Drug Name duvelisib
Key Synonyms duvelisib
Originator Company Intellikine Inc
Active Companies Yakult Honsha Co Ltd, Verastem Oncology
Infinity Pharmaceuticals Inc, Intellikine Inc, Mundipharma International Corp

Inactive Companies
Ltd, AbbVie Inc
Highest Status Pre-registration
Peripheral T-cell lymphoma, Follicle center lymphoma, Non-Hodgkin

Active Indications lymphoma, Hematological neoplasm, Lymphoma, T-cell lymphoma, Chronic
lymphocytic leukemia
Phosphoinositide-3 kinase delta inhibitor, Phosphoinositide-3 kinase gamma
Target-based Actions
inhibitor
Other Actions Apoptosis stimulator, Immunosuppressant, Anticancer protein kinase inhibitor
Technologies Oral formulation, Small molecule therapeutic
Last Change Date 11-Aug-2018
defactinib
Drug Name defactinib
Key Synonyms defactinib hydrochloride, defactinib
Originator Company Pfizer Inc
Active Companies Verastem Oncology
Inactive Companies Pfizer Inc
Highest Status Phase 2 Clinical
Cancer, Mesothelioma, Non-small-cell lung cancer, Pancreas tumor, Ovary

Active Indications
tumor, Solid tumor
Target-based Actions Focal adhesion kinase inhibitor, Focal adhesion kinase-2 inhibitor
Other Actions Apoptosis stimulator, Anticancer protein kinase inhibitor, Synergist
Technologies Oral formulation, Capsule formulation, Small molecule therapeutic
Last Change Date 19-Jul-2018

VS-5584
Drug Name VS-5584
Key Synonyms
Originator Company S*BIO Pte Ltd
Inactive Companies S*BIO Pte Ltd
Active Indications Mesothelioma, Cancer
mTOR inhibitor, Phosphoinositide-3 kinase alpha inhibitor, Phosphoinositide 3-

Target-based Actions
kinase inhibitor, mTOR complex 1 inhibitor, mTOR complex 2 inhibitor
Apoptosis stimulator, Anticancer protein kinase inhibitor, Synergist, Cell cycle
Other Actions
inhibitor
Last Change Date 26-Aug-2016
VS-4718
Drug Name VS-4718
Key Synonyms
Originator Company Scripps Research Institute
University of California San Diego, Scripps Research Institute, Poniard

Inactive Companies
Pharmaceuticals Inc
Active Indications Cancer
Target-based Actions Focal adhesion kinase inhibitor
Other Actions Apoptosis stimulator, Anticancer protein kinase inhibitor, Synergist
Last Change Date 17-May-2018

VS-6062
Drug Name VS-6062
Key Synonyms
Originator Company Verastem Oncology
Inactive Companies
Highest Status Discovery
Active Indications Non-small-cell lung cancer
Target-based Actions Focal adhesion kinase inhibitor
Other Actions Apoptosis stimulator, Anticancer protein kinase inhibitor
Technologies Small molecule therapeutic
Last Change Date 27-Apr-2015

This report was created by Clarivate Analytics, using information from Cortellis for Competitive Intelligence;
a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely
respected drug pipeline information.
For more information about Cortellis for Competitive Intelligence, visit:

https://clarivate.com/products/cortellis/
For subscription information, visit

https://clarivate.com/products/cortellis/cortellis-
competitive-intelligence/contact-us/
© 2017 Clarivate Analytics. All rights reserved.

Republication or redistribution of Clarivate Analytics
content, including by framing or similar means, is
prohibited without the prior written consent of Clarivate
Analytics. Clarivate and its logo are trademarks of the
Clarivate Analytics group.

VSTM Report3 PDF

Hochgeladen von

Dokumentinformationen

Originaltitel

Copyright

Verfügbare Formate

Dieses Dokument teilen

Dokument teilen oder einbetten

Freigabeoptionen

Stufen Sie dieses Dokument als nützlich ein?

Sind diese Inhalte unangemessen?

Copyright:

Verfügbare Formate

VSTM Report3 PDF

Hochgeladen von

Copyright:

Verfügbare Formate

Verastem Oncology

CORTELLIS COMPANY AND PIPELINE OVERVIEW REPORT

Tel: +1 888 537 6110

Return to Table of Contents

© 2018 Clarivate Analytics

Return to Table of Contents

© 2018 Clarivate Analytics 2

Return to Table of Contents

© 2018 Clarivate Analytics 3

Return to Table of Contents

© 2018 Clarivate Analytics 4

Return to Table of Contents

© 2018 Clarivate Analytics 5

Parent Company Name Verastem Oncology

Number of Inactive Drugs 3

Number of Patents as Owner 11

Return to Table of Contents

© 2018 Clarivate Analytics 6

In July 2011, Verastem raised $32 million from a series B financing.

In November 2010, Verastem raised $16 million from a series A financing.

Close Price (USD)

Previous Close Price (USD)

52-Week High (USD)

52-Week Low (USD)

Return to Table of Contents

© 2018 Clarivate Analytics 7

EPS (Date Reported) -1.76467

Shareholder Type Country Shares % of Change in % changes Date

Fidelity Select Mutual United

Vanguard Total Stock Mutual United

iShares Russell 2000 Mutual United

Vanguard Extended Mutual United

LSP Life Sciences Fund Mutual Netherla

Return to Table of Contents

© 2018 Clarivate Analytics 8

iShares Russell 2000 Mutual United

Fidelity Extended Mutual United

Fidelity Total Market Mutual United

Victory RS Science and Mutual United

Virtus LifeSci Biotech Mutual United

SEI Inst Inv Small Cap Mutual United

Return to Table of Contents

© 2018 Clarivate Analytics 9

2013 2016 2015 2014 2017

Operating Income (USD M) -41.402 -37.002 -58.199 -53.607 -67.804

Net Income (USD M) -41.202 -36.44 -57.865 -53.365 -67.802

Return to Table of Contents

© 2018 Clarivate Analytics 10

Period Sales (USD M) Operating Income (USD M) Net Income (USD M)

2018 Q2 10 -18.194 -18.367

2018 Q1 0 -20.761 -21.05

2017 Q4 0 -18.052 -18.235

2017 Q3 0 -23.137 -23.126

2017 Q2 0 -13.467 -13.436

2017 Q1 0 -13.148 -13.005

2016 Q4 0 -11.8 -11.655

2016 Q3 0 -8.059 -7.922

2016 Q2 0 -8.709 -8.569

2016 Q1 0 -8.434 -8.294

2013 2014 2015 2016 2017

Cash & Short Term

Current Assets - Total 101.955 95.316 110.843 81.295 87.787

Property, Plant And